2003 Fiscal Year Final Research Report Summary
Development for new cancer vaccine using various kinds of epitope peptides
| Project/Area Number |
14571128
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
TSUNODA Takuya The University of Tokyo, The Institute of Medical Science, Lecturer, 医科学研究所, 講師 (30275359)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TAKAYAMA Takuya The University of Tokyo, The Institute of Medical Science, Research Associate, 医科学研究所, 助手 (10332579)
TAHARA Hideaki The University of Tokyo, The Institute of Medical Science, Professor, 医科学研究所, 教授 (70322071)
|
|---|
| Project Period (FY) |
2002 – 2003
|
| Keywords | Epitope peptide / HER2 / neu / p53 / CTL / Cancer vaccine |
|---|
| Research Abstract |
Recently, cancer vaccine using epitope peptides was performed all over the world. Epitope peptides induced the strong cytotoxic T lymphocytes (CTL) in cancer patients, therefore clinical trials of cancer vaccine were performed. However, the outcome of clinical trial has not so excellent. One of the reasons was due to the only one target against the cancer. To promote the clinical efficacy, it is important to find the more epitope peptides. In this study, we determined the epitope peptides from HER2/neu and p53 which were significant molecules for cancer. We determined epitope peptides restricted to HLA-A*2402 which was the most common in Japanese. These findings may suggest that mixture of the epitope peptides improve the clinical efficacy of cancer vaccine.
|
